id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
S12836 R48364 |
Thomas (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.24 [0.26;19.12] C excluded (control group) |
6/137 1/50 | 7 | 137 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S12838 R48376 |
Thomas (Phenobarbital) (Controls unexposed, sick), 2021 | Cardiac malformations | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 1.68 [0.59;4.83] C | 6/137 9/340 | 15 | 137 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9151 R31457 |
Tomson (Phenobarbital), 2018 | Cardiac malformations | at least 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No | 4.66 [1.96;11.09] C | 8/294 15/2,514 | 23 | 294 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9107 R31284 |
Hernández-Díaz (Phenobarbital) (Controls exposed to Lamotrigine, sick), 2012 | Cardiovascular anomalies | 1st trimester | prospective cohort | exposed to other treatment, sick | Adjustment: No Controls: mixed indications | 13.39 [3.18;56.48] C | 5/199 3/1,562 | 8 | 199 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9124 R31346 |
Bànhidy (Phenobarbital), 2011 | Cardiovascular congenital abnormalities | throughout pregnancy | case control | unexposed, sick | Adjustment: No Matched | 2.11 [0.04;124.53] C | 0/ 5/15 | 5 | 0 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9101 R31181 |
D'Souza (Phenobarbital) (Controls unexposed, disease free), 1991 | Heart disease | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
73.80 [2.36;2304.87] C excluded (control group) |
1/4 0/62 | 1 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9102 R31210 |
D'Souza (Phenobarbital) (Controls unexposed, sick), 1991 | Heart disease | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 2.33 [0.11;50.99] C | 1/4 1/8 | 2 | 4 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9172 R31574 |
Van der Pol (Phenobarbital) (Controls unexposed, disease free), 1991 | Cardiac anomaly | throughout pregnancy | prospective cohort | unexposed, disease free excluded | Adjustment: No Matched |
1.55 [0.06;40.54] C excluded (control group) |
0/12 1/55 | 1 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
S9173 R31599 |
Van der Pol (Phenobarbital) (Controls unexposed, sick), 1991 | Cardiac anomaly | throughout pregnancy | prospective cohort | unexposed, sick | Adjustment: No | 1.87 [0.03;100.54] C | 0/12 0/22 | 0 | 12 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Total | 6 studies | 3.84 [1.95;7.54] | 53 | 646 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives |
1: Phenobarbital) (Controls unexposed, sick; 2: Phenobarbital; 3: Phenobarbital) (Controls exposed to Lamotrigine, sick; 4: Phenobarbital; 5: Phenobarbital) (Controls unexposed, sick; 6: Phenobarbital) (Controls unexposed, sick;
Asymetry test p-value = 0.8431 (by Egger's regression)
slope=1.4666 (0.6969); intercept=-0.2020 (0.9569); t=0.2111; p=0.8431
excluded 9101, 9172, 12836